HUB Organoids

#Advertorial #HUB Organoids #KRAS #Organoids

KRAS is no longer undruggable. Is your preclinical model ready?

In this paid-for advertorial for the Fall 2026 issue of DDW, HUB Organoids shares insight on KRAS inhibitor development.  KRAS inhibitor development has moved past single-allele chemistry into pan-RAS and combination strategies. HUB Organoids' patient-derived organoid platform gives your programme the resistance data, allele breadth, and combination evidence next-generation KRASi… Read More

#Exclusive Content

Organoids
#HUB Organoids #Organoids #Webinar

Closing the translation gap with patient-derived organoids

This advertorial appeared in DDW Volume 25 – Issue 4, Fall 2024 Read the digital issue Earlier this year, DDW hosted a webinar, ‘From patient to petri dish: Replicating disease with patient-derived organoids’, supported by HUB Organoids. The event explored how patient-derived organoids are revolutionising drug discovery by overcoming the limitations… Read More

#Exclusive Content

#Biomanufacturing #HUB Organoids #Molecular Devices #Organoids #UK #Wales

UK facility to manufacture organoids for drug discovery

A new facility has opened in Cardiff, UK designed to manufacture patient-derived organoids (PDOs) at scale for use in drug discovery and development. The multi-million-pound facility was custom-built by Molecular Devices to house its bioprocess workflow and bioreactor technology Mary Duseau, President of Molecular… Read More

#News